Utah Medical Products (UTMD)
NASDAQ:UTMD
Want to see UTMD full AI Analyst Report?
Top Page
Utah Medical Products
(NASDAQ:UTMD)
Select Model
Select Model
Rating:61Neutral
Price Target:
$69.00
▲(23.94% Upside)
Action:ReiteratedDate:05/05/26
The score is primarily constrained by the TTM cash-flow deterioration and ongoing revenue contraction, which outweigh the benefit of a very conservative balance sheet. Technicals are neutral-to-soft and valuation is reasonable with a modest dividend, providing some support but not enough to offset the fundamental cash-flow and growth concerns.
Positive Factors
Balance-sheet conservatism
Extremely low leverage and a sizable equity base give the company durable financial flexibility to fund operations, absorb volatility, and pursue targeted investments or small acquisitions without relying on external financing, reducing solvency risk over the medium term.
Negative Factors
Multi-year revenue decline
A sharp, multi-year top-line contraction materially weakens operating leverage and market positioning. Persistent revenue loss limits reinvestment capacity, risks erosion of distribution relationships, and makes restoring prior growth levels a multi-quarter structural challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet conservatism
Extremely low leverage and a sizable equity base give the company durable financial flexibility to fund operations, absorb volatility, and pursue targeted investments or small acquisitions without relying on external financing, reducing solvency risk over the medium term.
Read all positive factors
Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$205.91M
Dividend Yield2.15%
Average Volume (3M)15.88K
Price to Earnings (P/E)19.0
Beta (1Y)0.61
Revenue Growth-4.43%
EPS GrowthN/A
CountryUS
Employees155
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)3.40
Shares Outstanding3,185,025
10 Day Avg. Volume20,525
30 Day Avg. Volume15,884
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)1.55
Price to Sales (P/S)4.81
P/FCF Ratio12.93
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue3.08
Enterprise Value/Gross Profit5.82
Enterprise Value/Ebitda7.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Utah Medical Products Business Overview & Revenue Model
Company Description
Utah Medical Products, Inc. (UTMD) is a leading medical device company focused on developing and manufacturing high-quality medical products primarily for the healthcare sector. Founded in 1978 and headquartered in Midvale, Utah, the company speci...
How the Company Makes Money
UTMD makes money primarily by selling medical devices and related disposable products (single-use or repeat-purchase consumables) used in clinical procedures, with revenue recognized from product shipments to healthcare providers and distributors....
Utah Medical Products Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.52M | 40.90M | 50.22M | 52.28M | 49.05M |
| Gross Profit | 19.88M | 24.14M | 30.04M | 32.20M | 30.92M |
| EBITDA | 17.06M | 16.44M | 24.75M | 26.87M | 26.16M |
| Net Income | 11.29M | 13.87M | 16.64M | 16.47M | 14.79M |
Balance Sheet | |||||
| Total Assets | 122.54M | 122.54M | 135.46M | 123.87M | 115.64M |
| Cash, Cash Equivalents and Short-Term Investments | 85.76M | 82.98M | 92.87M | 75.05M | 60.97M |
| Total Debt | 225.00K | 338.00K | 295.00K | 341.00K | 396.00K |
| Total Liabilities | 3.27M | 5.11M | 7.14M | 9.62M | 8.50M |
| Stockholders Equity | 119.27M | 117.43M | 128.31M | 114.25M | 107.14M |
Cash Flow | |||||
| Free Cash Flow | 14.32M | 14.60M | 21.64M | 20.33M | 20.65M |
| Operating Cash Flow | 14.69M | 14.83M | 22.28M | 21.15M | 21.20M |
| Investing Cash Flow | -371.00K | -208.00K | -639.00K | -818.00K | -552.00K |
| Financing Cash Flow | -12.34M | -23.84M | -4.17M | -5.48M | -10.90M |
Utah Medical Products Technical Analysis
Positive
55.67
Price Trends
64.77
Positive
61.30
Positive
59.85
Positive
Market Momentum
1.42
Negative
72.61
Negative
93.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 55.67 is below the 20-day moving average (MA) of 65.02, below the 50-day MA of 64.77, and below the 200-day MA of 59.85, indicating a bullish trend. The MACD of 1.42 indicates Negative momentum. The RSI at 72.61 is Negative, neither overbought nor oversold. The STOCH value of 93.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.
Utah Medical Products Risk Analysis
Utah Medical Products disclosed 9 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Utah Medical Products Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $209.82M | 22.36 | 11.91% | ― | 6.36% | 193.82% | |
61 Neutral | $205.91M | 18.96 | 9.56% | 2.15% | -4.43% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $189.49M | -137.80 | -15.89% | ― | 22.23% | 56.80% | |
46 Neutral | $174.04M | -31.27 | -178.57% | ― | 19.01% | -282.10% |
* Healthcare Sector Average
UTMD
Utah Medical Products
64.65
13.43
26.23%
INFU
InfuSystem Holdings
10.39
5.61
117.36%
KRMD
REPRO-MED Systems
3.99
1.23
44.57%
SMTI
Sanara MedTech
18.99
-13.37
-41.32%
STSS
Sharps Technology, Inc.
1.83
-2.82
-60.65%
Utah Medical Products Corporate Events
Executive/Board ChangesShareholder Meetings
Utah Medical Shareholders Back Board, Auditor and Pay Policies
Positive
May 4, 2026
On May 1, 2026, Utah Medical Products stockholders voted on key governance and compensation matters at the company’s annual meeting, including the election of directors, ratification of the auditor, and an advisory say-on-pay resolution. Sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.